PODD Stock Analysis — Insulet
Sector: Healthcare
AI Verdict
At 20.0x forward earnings for 83.2% expected EPS growth, this is cheap for the growth you're getting—assuming Insulet's closed-loop system keeps its edge against larger diabetes device rivals.
Competitive Moat
Insulet makes the Omnipod, a tubeless, wearable insulin pump that automates insulin delivery for diabetics, offering a lifestyle advantage over traditional pumps. The moat comes from its proprietary pod design and FDA-cleared closed-loop system, which create high switching costs and recurring consumables revenue.
Summary
Omnipod's wearable insulin pump is driving a rapid shift from traditional pumps, with analysts expecting 83.2% EPS growth next year.
Where It Stands
Shares are down -47.07% over the past year, trade at 20.0x forward earnings (below the healthcare median of 22x), and the RSI at 58.0 signals a neutral setup.
Key Metrics
- RSI: 58 — Neutral
- Trailing P/E: 36.6x
- Forward P/E: 20.0x
- PEG Ratio: 0.43
- Earnings Growth: +0.8%
- Revenue Growth: +0.3%
- Market Cap: $10.9B
- 1-Year Return: -47.07%
- 52-Week High: $354.88
- 52-Week Low: $138.79
Analyst Consensus
30 Buy · 5 Hold · 0 Sell (35 analysts)
Bull Case
With forward EPS expected to jump 83.2% and a forward P/E of 20.0x, you're paying a below-average price for unusually high growth if Omnipod adoption keeps accelerating.
Bear Case
If the forward P/E reverts to the sector median of 22x without delivering on 83.2% EPS growth, the stock could stagnate or fall further after a -47.07% one-year return.
Catalyst to Watch
Watch for FDA approvals or clinical data on Omnipod expansion, as positive results could validate the 83.2% EPS growth baked into estimates.